| Přispěvatelé: |
UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - Faculté de médecine et médecine dentaire, Jonas, Jean-Christophe, Vanoverschelde, Jean-Louis, Vancraeynest, David, Dessy, Chantal, Coulie, Pierre, Beauloye, Christophe, Horman, Sandrine |
| Popis: |
Platelets are central actors in atherosclerosis and atherothrombosis. Stimulation of the AMP-activated protein kinase (AMPK) leads to phosphorylation and inhibition of acetyl-CoA carboxylase (ACC), the first committed enzyme for the de novo fatty acids synthesis in cells, including platelets. Given the impact of atherogenic environment on platelets, we hypothesized that AMPK-ACC signaling is activated in coronary artery disease (CAD) patients. The ACCTHEROMA trial (NCT03034148) reveals platelet ACC phosphorylation (phosphoACC) as a promising marker for risk stratification in suspected CAD patients. It identifies high-risk patients and correlates with severity of coronary artery calcification. The triglycerides/high-density lipoprotein cholesterol ratio is strongly associated with increased phosphoACC, a metabolic signature of the platelet-atherogenic lipid interplay in CAD patients. Phosphorylation and inhibition of ACC impacts platelet lipid content by down-regulating triglyceride lipid species, which in turn may affect platelet functions. (MED - Sciences médicales) -- UCL, 2019 |
